TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00900887
Drug: Polietilenglicol 400, propilenglicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week
Study: NCT04302025
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
Study: NCT02085005
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01461369
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 35 mg bid Capsules
Study: NCT01461369
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 35 mg tid Capsules
Study: NCT02378467
Drug: 7% Hypertonic Saline (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
Study: NCT02228369
Drug: AZD3759
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
Study: NCT02228369
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 160mg once daily
Study: NCT00006103
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006103
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03521102
Drug: Acetaminophen 1000mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
Study: NCT00053599
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01226615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules taken once a day for four months.
Study: NCT02868814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03106766
Drug: Acne cream 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of facial acne cream 2X after facial cleansing
Study: NCT03106766
Drug: Acne cream 1X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of facial acne cream 1X after facial cleansing
Study: NCT03056599
Drug: Multiple drug microinjection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
Study: NCT04876807
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
Study: NCT00561093
Drug: Placebo pill imitating pentoxiphylline
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study: NCT02622334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo formulation will be administered in Part A.
Study: NCT02622334
Drug: RO5093151
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
Study: NCT01533129
Drug: Testosterone 250mg injection
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The testosterone 250mg ester IM injections performed in three weeks.
Study: NCT03094663
Drug: Bupivacaine with epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% with epinephrine 30cc
Study: NCT04637009
Drug: TAS1553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: tablet; Route of Administration: oral
Study: NCT03615326
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
Study: NCT03224598
Drug: A-101 Topical Solution 40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 Topical Solution 40%
Study: NCT04254042
Drug: Perindopril Arginine
Normalized name: Perindopril Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study: NCT01910597
Drug: SBG
Normalized name: PSBG - Pregnancy specific beta 1-glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03283007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
Study: NCT04254042
Drug: Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study: NCT00140361
Drug: lumefantrine plus artemether
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02533505
Drug: Matching Placebo pMDI 160/4.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
Study: NCT01254994
Drug: Traditional comprehensive medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
Study: NCT04175509
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal 1300mg
Study: NCT04175509
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1000mg
Study: NCT02484859
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
Study: NCT04061057
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min.
Study: NCT00893867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
Study: NCT04144218
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
Study: NCT00730028
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
Study: NCT02172183
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate or atomoxetine
Study: NCT00172094
Drug: NPS 1776 (800 mg)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPS 1776 (800 mg) powder
Study: NCT00172094
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in non-carbonated fruit flavored drink (150 ml)
Study: NCT01284231
Drug: MEDI-565
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-565 will be administered by IV infusion
Study: NCT01284231
Drug: MEDI-565
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
Study: NCT01284231
Drug: MEDI-565
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
Study: NCT00523887
Drug: Fentanyl transdermal therapeutic system
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01225237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01864226
Drug: RO5545965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT01864226
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT03336645
Drug: SHP615
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Study: NCT01351909
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02561923
Drug: Kcentra, a 4-factor PCC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
Study: NCT03596060
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
Study: NCT04034095
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
Study: NCT02307565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Study: NCT00613054
Drug: Zactima, Gleevec, Hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations.
Study: NCT01701843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical treatment for 14 days
Study: NCT03121989
Drug: Hyperpolarized Pyruvate (13C) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
Study: NCT03794999
Drug: Exposure to other asthma medications
Normalized name: zinc pyrithione Medicated Liquid Soap [Born To Be Mild]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
Study: NCT01547780
Drug: [11C]PBR28 and Positron Emission Tomography (PET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
Study: NCT02108366
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg daily
Study: NCT00280111
Drug: I321
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of I321 10\^5 FFu
Study: NCT00280111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
Study: NCT04522336
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04365907
Drug: Zafatek tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly new anti-diabetic drug approved only in Japan
Study: NCT01366365
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04078087
Drug: Non obese
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Study: NCT04078087
Drug: Obese.
Approvals — FDA: no, EMA: no, PMDA: no
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Study: NCT02555683
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 150 mg once daily
Study: NCT02555683
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 450 mg once daily
Study: NCT02555683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT02576002
Drug: Assigned pulmonary hypertension medication
Normalized name: Antihypertensives for pulmonary arterial hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
Study: NCT00003594
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003594
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04316065
Drug: YHP1906
Approvals — FDA: no, EMA: no, PMDA: no
Description: YHP1906 Tab. 5 mg
Study: NCT04316065
Drug: YHR1902
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator. YHR1902 Tab. 5 mg
Study: NCT01415284
Drug: Hydroxyethylstarch 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
Study: NCT03865706
Drug: Placebo Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
Study: NCT00603590
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablet Once a day Identical in appearance to intervention drug
Study: NCT04493515
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo orally (24 IU)
Study: NCT03865706
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment for infections
Study: NCT02685020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Study: NCT05152004
Drug: Klaricid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
Study: NCT00916292
Drug: FGF-1 141
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
Study: NCT01288976
Drug: Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
Study: NCT00916292
Drug: FGF-1 141
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
Study: NCT01111929
Drug: Counseling for LAM+ LNG-EC
Normalized name: Viril Lam
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.
Study: NCT02218476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00913861
Drug: standard sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
Study: NCT00817687
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed; + early biopsy
Study: NCT00817687
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed; + standard treatment
Study: NCT01490723
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
Study: NCT01876433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04215003
Drug: CL4
Normalized name: Mills CL43 MLS 16,20DR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
Study: NCT02713256
Drug: CFZ533
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFZ533 intravenously over approximately one hour
Study: NCT01124630
Drug: CS-1008
Normalized name: MyoGesic-CS
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.